Likvor new LinkMed portfolio company

Press release
November 8, 2007


Likvor new LinkMed portfolio company

LinkMed is investing SEK 4 million in the medtech company Likvor AB, which will
thereby become the 12th company in LinkMed's portfolio.  Likvor is developing an
instrument to measure cerebrospinal fluid pressure. The company is currently
carrying out a multi-center study at five university hospitals in Sweden and
Denmark.

Cerebrospinal fluid is the fluid found in the cavity of the brain and the spinal
channel. Patients with changes in the pressure of this fluid often show
different symptoms, such as changes in personality, dementia, disturbances in
balance, irritation, headaches and vomiting. The pressure can be evened out by
operating a shunt into the brain. 

Today, there are no commercially available methods for measuring cerebrospinal
fluid in a safe and successful way. As a rule, patients with problems related to
high pressure are identified in healthcare checkups. However, patients with
normal or low pressure sometimes experience symptoms such as disturbance in
balance or dementia-like symptoms and are harder to identify. 

The Västerbotten county council and the institution of clinical neuroscience at
Umeå University, have carried out extensive research on the measurement of
pressure in the brain and cerebrospinal fluid. This has resulted in an
instrument that can safely and effectively measure cerebrospinal fluid pressure.
The instrument has been used on more than 1,000 patients at the Umeå University
Hospital, creating valuable clinical material.

Likvor AB, established by Uminova Invest in 2007, has acquired the instrument
and related patents in order to develop a commercial product. The company is
currently carrying out a multi-center study at five university hospitals in
Sweden and Denmark, which will form the basis for the commercial design of the
product. It is estimated that clinical work will be completed at the end of
2007, after which the results will be compiled and analyzed.

LinkMed's investment is being made in conjunction with a new share issue from
Likvor for a total of SEK 5.5 million to finance this development work. LinkMed
is investing SEK 4 million and as a result will have an ownership stake of 49
percent in the company. The investment is pending certain conditions.



For additional information please contact:
Ingemar Lagerlöf, CEO LinkMed	, +46 8 508 939 93


LinkMed develops new life-science companies in collaboration with innovators. By
contributing entrepreneurship and capital, LinkMed has created a portfolio of
eleven companies, six in drug development and biotechnology and five in medical
technology. The LinkMed share is listed on the OMX Nordic Exchange, Stockholm,
and the company's largest shareholders are FastPartner, Koncentra Holdin and the
founder Ingemar Lagerlöf. See www.linkmed.se for more information.